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/18 Abstract
/19
/20 A recombinant baculovirus expressing membrane bound form of hemagglutinin/neuraminidase (HN) protein of
/21 peste des petits ruminants virus (PPRV) was employed to generate monoclonal antibodies (mAbs) against PPRV-HN
/22 protein. Four different mAbs were employed for mapping of regions on HN carrying B-cell epitopes using deletion
/23 mutants of PPRV-HN and RPV-H proteins expressed in Escherichia coli as well as PPRV-HN deletion proteins
/24 expressed transiently in mammalian cells. The immuno-reactivity pattern indicated that all mAbs bind to two
/25 discontinuous regions of amino acid sequence 263/368 and 538/609 and hence the epitopes identified are
/26 conformation-dependent. The binding regions for three mAbs were shown to be immunodominant employing
/27 competitive ELISA with vaccinated sheep sera. Delineation of functional domains on PPRV-HN was carried out by
/28 assessing the ability of these mAbs to inhibit neuramindase activity and hemagglutination activity. Two mAbs inhibited
/29 NA activity by more than 63% with substrate N -acetyl neuraminolactose, while with Fetuin one mAb showed
/30 inhibition of NA activity (95%). Of the three antigenic sites identified based on competitive inhibition assay, site 2 could
/31 be antigenically separated into 2a and 2b based on inhibition properties. All the four mAbs have virus neutralizing and
/32 recognized PPRV-HN in immunofluorescence assay. # 2002 Elsevier Science B.V. All rights reserved.
/33 Keywords: Peste des petits ruminants virus; Hemagglutinin/neuraminidase protein; Monoclonal antibodies; Conformational epitopes;
/34 Functional domains
/ 351. Introduction
/ 36Peste des petits ruminants (PPR), also known as
/ 37‘‘goat plague’’, is an acute, highly contagious viral
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/38 disease of goat and sheep, caused by peste des
/39 petits ruminants virus (PPRV) which is a member
/40 of the genus Morbillivirus under the family Para-
/41 myxoviridae. PPRV is widespread across sub-
/42 Saharan Africa and the Arabian Peninsula (Tay-
/43 lor, 1984). Epizootics are more frequent in western
/44 Africa and enzootics occur mainly in arid and
/45 semi-arid areas of Africa. When the first outbreak
/46 was diagnosed to be due to PPRV (Shaila et al.,
/47 1989), the disease was not known to exist in India
/48 till 1988 and since then has been reported in
/49 different parts of India (Kulkarni et al., 1996;
/50 Nanda et al., 1996; Govindarajan et al., 1997).
/51 PPR introduces severe economic losses by causing
/52 high mortality and severe morbidity in infected
/53 caprines and ovines.
/54 PPRV has two surface glycoproteins*/the
/55 hemagglutinin/neuraminidase (HN) and fusion
/56 (F) proteins*/whose biological activities have
/57 been studied in isolation by transiently expressing
/58 the two genes in mammalian cells (Seth and Shaila,
/59 2001). HN recognizes the host cells receptors while
/60 F protein mediates the fusion of the viral envelope
/61 with the host cell membrane. Monoclonal anti-
/62 bodies (mAbs) have been widely employed in
/63 determining the antigenic sites and to identify the
/64 functional domains important for biological activ-
/65 ities on viral surface glycoproteins HN and F of
/66 paramyxo and morbilliviruses (Rydbeck et al.,
/67 1986; Portner et al., 1987; Komada et al., 1989).
/68 Though mAbs have been produced against PPRV-
/69 HN and nucleocapsid proteins (Libeau and Le-
/70 fevre, 1990; Anderson and McKay, 1994), anti-
/71 genic determinants on these proteins have not been
/72 mapped so far.
/73 Langedijk et al. (1997) predicted that two
/74 morbilliviruses*/PPRV and rinderpest virus
/75 (RPV)*/possess neuraminidase (NA) activity
/76 based on extensive comparison of secondary
/77 structures of all known NAs with the predicted
/78 secondary structures of HN and H proteins. PPRV
/79 has been shown to possess hemagglutination
/80 activity (Ramachandran et al., 1995). The NA
/81 activity of PPRV H protein was demonstrated
/82 after purifying the protein from infected cells or
/83 from purified virus, which also showed HA
/84 activity (Shyam and Shaila, unpublished results).
/85 The NA activity was conclusively demonstrated
/ 86using the cloned HN gene to transiently express
/ 87the HN protein transfected in mammalian cells
/ 88(Seth and Shaila, 2001). The host cell receptor for
/ 89PPRV was shown to be an NA sensitive structure
/ 90containing sialic acid linked in a2/3 linkage
/ 91(Shyam and Shaila, unpublished results).
/ 92In paramyxoviruses, functional inhibition stu-
/ 93dies have been carried out using mAbs to locate
/ 94the antigenic sites relative to the hemagglutinin
/ 95and NA activities (Iorio and Bratt, 1984). Four
/ 96distinct antigenic sites on HN of Sendai virus were
/ 97identified and the biological functions of HN were
/ 98related to its antigenic structure using anti-HN
/ 99antibodies in inhibition assays (Portner et al.,
/ 1001987).
/ 101Recently, neutralizing immunodominant epi-
/ 102topes on RPV-H have been mapped using selected
/ 103mAb-resistant mutants of lapinized strain of RPV
/ 104(Sugiyama et al., 2002). However, there is no
/ 105information concerning the major antigenic re-
/ 106gion(s) on the PPRV-HN protein. We have
/ 107generated a recombinant baculovirus expressing
/ 108HN protein of PPRV (Ind. AP94/1 strain) and
/ 109shown that the expressed protein gets incorporated
/ 110into extracellular baculovirus particles (rECV)
/ 111(Chattopadhyay et al., unpublished results).
/ 112Further, we demonstrated that rECV induces the
/ 113generation of virus neutralizing antibodies and
/ 114HN-specific lymphoproliferative responses in
/ 115goats (Sinnathamby et al., 2001a).
/ 116In this work, we report the development of
/ 117mAbs against PPRV-HN using rECV and char-
/ 118acterization of the antigenic determinants recog-
/ 119nized by these mAbs on PPRV-HN and RPV-H
/ 120proteins by employing overlapping deletion pro-
/ 121teins of PPRV-HN and RPV-H expressed in
/ 122Escherichia coli as well as eucaryotic cells. We
/ 123identified discontinuous regions on these proteins
/ 124recognized by mAbs and present indirect evidence
/ 125that the epitopes are conformation-dependent. We
/ 126have also attempted to delineate the functional
/ 127domains on PPRV-HN by evaluating the ability of
/ 128these mAbs to inhibit NA activity and hemagglu-
/ 129tination. Based on the mAb reactivities, the
/ 130regions on HN protein contributing to NA activity
/ 131have been identified.
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/132 2. Materials and methods
/133 2.1. Cells and viruses
/134 Vero cells (originally obtained from National
/135 Centre for Cell Science, Pune, India) were cultured
/136 in Dulbecco’s modified Eagle’s medium (DMEM,
/137 Himedia, India) supplemented with 5% fetal calf
/138 serum (FCS, Gibco BRL). Spodoptera frugiperda
/139 (Sf-21) insect cells were cultured in TC-100 med-
/140 ium (Gibco BRL) supplemented with 10% fetal
/141 bovine serum (FBS, Gibco BRL). Sp2/0 myeloma
/142 cells and hybridoma cells were cultured in Iscove’s
/143 modified Dulbecco’s medium (IMDM, Gibco
/144 BRL), supplemented with 10% FBS. A recombi-
/145 nant baculovirus expressing PPRV-HN was pro-
/146 pagated in Sf-21 cells as described earlier
/147 (Sinnathamby et al., 2001a). Vaccine strains of
/148 PPRV Nig75/1 and RPV (RBOK) were propa-
/149 gated in Vero cells. Parental clones of hybridoma
/150 were selected using IMDM supplemented with
/151 HAT (hypoxanthine, aminopterin and thymidine,
/152 Gibco BRL) and HT (hypoxanthine and thymi-
/153 dine, Gibco BRL, USA). Chicken (Galus galus )
/154 erythrocytes (RBCs) were collected by wing vein
/155 puncture from birds that were housed at the
/156 Institute of Animal Health and Veterinary Biolo-
/157 gicals, Bangalore.
/158 2.2. Production of recombinant PPRV-HN
/159 extracellular virus
/160 Recombinant baculovirus expresses the PPRV-
/161 HN protein on the surface of assembled virus
/162 particles released from infected cells as extracel-
/163 lular virus (ECV) particles. The rECV was purified
/164 from the supernatant collected from Sf-21 cells
/165 infected with the virus at an moi of 5, employing
/166 sucrose density gradient centrifugation method
/167 described by Summers and Smith (1987). The
/168 protein content in the purified virus was estimated
/169 by the method of Lowry et al. (1951).
/170 2.3. Titration of virus stocks by TCID50 assay
/171 Confluent Sf-21 cell monolayer was harvested
/172 and the cells were resuspended in TC-100 medium
/173 supplemented with 10% FBS at a density of 1/
/ 174105 cells/ml. The virus stock was thawed in a
/ 17537 8C water bath. Tenfold dilutions of the virus
/ 176were prepared in complete medium. Virus dilu-
/ 177tions (100 ml) were added in replicates to the wells
/ 178of a 96-well tissue culture plate. Cell suspension
/ 179(100 ml) containing 104 cells/well was then added to
/ 180the wells and the plate was incubated at 27 8C
/ 181incubator. The plate was monitored every day for
/ 1824 days and the appearance of CPE was recorded.
/ 183TCID50 was calculated by employing Reed and
/ 184Muench formula (Burleson et al., 1992).
/ 1852.4. Deletion mutants of PPRV-HN and RPV-H
/ 186proteins
/ 187Generation of deletion mutants of RPV-H and
/ 188PPRV-HN protein, expression as His-tagged fu-
/ 189sions in E. coli strain BL21(DE3) and their
/ 190purification have been described earlier (Sin-
/ 191nathamby et al., 2001a,b). The deletion mutants
/ 192of PPRV-HN, ND241 and ND262CD101 and
/ 193RPV-H deletions: ND448, ND511, ND359; CD41,
/ 194ND112; D183/424; CD160, ND356; CD185 and
/ 195ND112; CD427, employed in this study are sche-
/ 196matically represented in Fig. 3A(i) and (iii).
/ 197Five deletion gene constructs of PPRV-HN
/ 198(CD241; D385/537; ND508; D80/368 and
/ 199CD412) are schematically represented in Fig. 3(ii)
/ 200were generated in a eucaryotic expression vector
/ 201pCMX under a cytomegalovirus promotor. The
/ 202parental clone pSSHNCMX and pGEM. PPRV-
/ 203HN was used to construct the deletion mutants
/ 204used in this study. DNA digestions were carried
/ 205out using appropriate amounts of enzymes and the
/ 206insert fragments and dephosphorylated vectors
/ 207were gel eluted from LMP agarose prior to
/ 208ligation. Extracts prepared from CV1 cells trans-
/ 209fected with the plasmids carrying different frag-
/ 210ments of HN gene were used in ELISA. Briefly,
/ 211CV1 cells were plated in DMEM containing 5%
/ 212FCS, when the cells were 70% confluent washed
/ 213the cells with 1/ PBS then lipofectamine (2 mg/
/ 214ml) or polyethylene imine (PEI) (1 mg/ml, pH 7.0)
/ 215and 7 mg of DNA were mixed in OPTI-MEM and
/ 216after incubation for 30 min at room temperature
/ 217added to the cells and incubated. The transfection
/ 218mix was then removed completely, and DMEM
/ 219was added and left for 24 h at 37 8C.
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/220 2.5. Recombinant baculovirus infected cell extract
/221 Sf-21 cells infected with the recombinant bacu-
/222 lovirus for 72 h with an moi of 5 were resuspended
/223 in PBS and sonicated in a Vibracell (USA)
/224 ultrasonic processor and then the lysed suspension
/225 was clarified at 10,000/g for 10 min. The super-
/226 natant collected was used in indirect ELISA.
/227 2.6. PPRV Nig 75/1, PPRV TN 87/1 and RPV
/228 (RBOK) infected cell extract
/229 PPRV Nig 75/1, PPRV TN87/1 and RPV
/230 (RBOK) viruses were grown in Vero cells. At
/231 60/70% confluency, Vero cells were infected at
/232 moi 10. After 48/72 h when 60/70% CPE was
/233 apparent, cell extract was prepared as described
/234 above.
/235 2.7. Generation of hybridoma for PPRV-HN
/236 Balb/c mice were immunized subcutaneously (s/
/237 c) with 500 mg of purified rECV (the HN protein
/238 content in rECV is estimated to be 8/10% of the
/239 total protein, Chattopadhyay et al., unpublished
/240 observation) in Freund’s complete adjuvant
/241 (FCA). Mice were boosted s/c twice with 250 mg
/242 of rECV in Freund’s incomplete adjuvant at 3
/243 weeks interval. A week following the second
/244 booster injection, mice were bled and HN-specific
/245 ELISA titers were determined. A titer of 1:10,000
/246 was considered optimum for proceeding with the
/247 fusion. Three weeks after the second booster, mice
/248 were further boosted with 500 mg of purified rECV
/249 intraperitonealy. Four days later, one of the
/250 immunized animals was sacrificed and spleen cells
/251 were fused with Sp2/0 myeloma cells by standard
/252 PEG-mediated fusion protocol (Bhavani et al.,
/253 1989).
/254 2.8. Western blot analysis of the recombinant
/255 proteins
/256 After electrophoresis of equal amounts of dele-
/257 tion proteins (protein content determined using
/258 Pierce Coomassie protein assay kit), the separated
/259 proteins were electroblotted onto nitrocellulose
/260 membrane, blocked in 3% gelatin in PBS, and
/ 261probed with appropriately diluted mAbs. Blots
/ 262were developed using H2O2 and diaminobenzidine
/ 263(DAB) in PBS.
/ 2642.9. Indirect ELISA
/ 265ELISA plates were coated with PPRV Nig 75/1
/ 266or RPV-RBOK infected Vero cell extracts at a
/ 267concentration of 1 mg/well for an hour at 37 8C or
/ 268overnight at 4 8C. The plate was washed in PBS
/ 269thrice and blocked with blocking buffer (3%
/ 270bovine gelatin/0.1% Tween-20 in PBS) for 1 h
/ 271at 37 8C. Plates were then treated with serial
/ 272dilutions of PPRV-HN-specific mouse hyperim-
/ 273mune sera/hybridoma culture supernatant/ascitic
/ 274fluid in PBS at 37 8C for an hour. Plates were
/ 275washed and treated with anti-mouse Ig-HRP or
/ 276anti-mouse IgM-HRP conjugate at 37 8C for an
/ 277hour. The reaction was developed using O -pheny-
/ 278lenediamine dihydrochloride and H2O2 and termi-
/ 279nated using 2 N H2SO4. Plates were then read in a
/ 280microtiter plate reader at 490 nm. Supernatant
/ 281collected from each established hybridoma clone
/ 282was subjected to an isotyping ELISA using an
/ 283isotyping kit (Boehringer Mannheim, Germany)
/ 284according to the directions of the manufacturers.
/ 2852.10. Competition ELISA for HRP conjugated
/ 286mAbs
/ 287Ascitic fluids from mice injected with three mAb
/ 288clones (C10A1, D2E4 and F10E7) were subjected
/ 289to ammonium sulphate precipitation at 50%
/ 290saturation according to Harlow and Lane (1988).
/ 291The concentration of precipitated protein was
/ 292determined by Lowry method (Lowry et al.,
/ 2931951). Concentrated mAb preparations were then
/ 294coupled to HRP by standard procedures (Harlow
/ 295and Lane, 1988). ELISA plates were coated with
/ 296PPRV Nig 75/1 infected Vero cell extracts (1 mg/
/ 297well) and blocked with blocking buffer. The
/ 298reaction was developed and read as described for
/ 299indirect ELISA. Percent inhibition (PI) of con-
/ 300jugated mAb by the unconjugated mAb is calcu-
/ 301lated using the following formula: PI/100/[A/
/ 302C]/[A/B]/100, wherein, A/OD490 in the ab-
/ 303sence of competitor (heterologous mAb), B/
/ 304OD490 in the presence of homologous mAb, C/
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/305 OD predetermined in the presence of competitor
/306 (heterologous mAb).
/307 2.11. Competitive ELISA for identifying
/308 immunodominant epitopes
/309 Competitive ELISA (C-ELISA) was performed
/310 essentially as described previously (Anderson and
/311 McKay, 1994). Briefly, the PPRV Nig 75/1 in-
/312 fected cell extract in PBS was used as an antigen
/313 for C-ELISA. Each well of a 96-well microtiter
/314 plate was coated with the antigen (5 mg/ml) at
/315 4 8C overnight and treated with blocking buffer
/316 (PBS supplemented with 0.1% (v/v) Tween-20 and
/317 0.3% (v/v) normal sheep serum seronegative for
/318 PPRV) for 1 h at 37 8C. After washing five times
/319 in phosphate buffer saline (0.2/ PBS), appro-
/320 priate dilutions of test sera (10 negative and 50
/321 positive sera) and anti-HN mAbs (A6E9, C10A1,
/322 D2E4 and F10E7) were added. Serum controls
/323 (strong positive, weak positive and negative sheep
/324 sera) and a mAb (0% competition) control were
/325 included. Following incubation at 37 8C for 1 h
/326 on an orbital shaker, plates were washed and anti-
/327 mouse HRPO conjugate (predetermined dilution)
/328 was added. After a final incubation, substrate/
/329 chromogen (OPD/H2O2) was added and the color
/330 allowed to develop for 10/15 min. Plates were
/331 read on ELISA reader at 490 nm, and analyzed
/332 using an enzyme immunoassay (EIA) software
/333 (Biologicals Diagnostic Supplies Ltd., UK) and
/334 the OD values were converted to percentage
/335 inhibition (PI) values using the following formula.
/336 PI/100/[OD in test well/OD in 0% control
/337 well]/100.
/338 Out of 60 test sera (10 negative and 50 positive
/339 for PPRV antibodies) used in C-ELISA were
/340 collected from five different vaccinated herds.
/341 From each herd, 10 positive and two negative
/342 were collected and subjected for C-ELISA with all
/343 the four PPRV-HN mAbs separately.
/344 2.12. Immunofluorescence
/345 Vero cells grown on cover slips were infected
/346 with RPV (RBOK) and PPRV (Nig 75/1) at 10
/347 moi and when the cells showed 30/40% cytopathic
/348 effect (CPE), cover slips were washed gently in
/ 349PBS. Acetone fixed cells (intra-cytoplasmic detec-
/ 350tion) or unfixed cells were used for immunofluor-
/ 351escence as described by Harlow and Lane (1988).
/ 3522.13. NA and NI assays
/ 353NA assay was performed according to Aymard-
/ 354Henry et al. (1973). For neuraminidase inhibition
/ 355(NI) assay, PPRV Nig 75/1 infected cell extract
/ 356(dilution which gave the OD of 0.6 in NA activity)
/ 357was mixed with double diluted ascites of different
/ 358PPRV-HN mAbs with an initial dilution of 1 in 5
/ 359in PBS and the assay was performed. The OD
/ 360values obtained for each dilution of the ascites was
/ 361then expressed as percentage activity remaining
/ 362using the following formula:
363NI activity (%)


OD of the test mAb after inhibition
OD of the virus control

100:
/ 3642.14. Hemagglutination and hemagglutination
/ 365inhibition assays
/ 366Hemagglutination assay was performed accord-
/ 367ing to Rosanff (1961). For hemagglutination
/ 368inhibition (HI) assay, ascitic fluids were double
/ 369diluted in PBS in a volume of 25 ml starting with an
/ 370initial dilution of 1 in 5 in a round bottom 96-well
/ 371plate. Twenty-five microliters of four HA units of
/ 372PPRV antigen (PPRV Nig 75/1 infected cell
/ 373extract) was added to the wells. Then the standard
/ 374procedure of HI was followed (Norrby, 1962).
/ 3752.15. Virus neutralization assay
/ 376The ability of mAbs to neutralize virus infectiv-
/ 377ity was tested using the procedures described by
/ 378Barrett et al. (1989). Briefly, equal volumes (25 ml)
/ 379of twofold dilutions of heat-inactivated (56 8C, 1
/ 380h) ascitic fluid and PPRV (Nig 75/1 strain, 100
/ 381TCID50) or RPV (RBOK strain, 100 TCID50) were
/ 382mixed in 96-well flat bottom tissue culture plates.
/ 38350 ml of trypsinized Vero cells resuspended at 105
/ 384cells/ml in DMEM containing 5% fetal calf serum
Y:/Elsevier Science/Shannon/Virus/articles/virus2255/VIRUS2255.3d[x] Monday, 26th August
G.J. Renukaradhya et al. / Virus Research 00 (2002) 1/15 5
ARTICLE IN PRESS
UN
CO
RR
EC
TE
D P
RO
OF
/385 were added to each well and the plates were
/386 incubated at 37 8C for 3 days. Serum controls,
/387 cell controls, and virus controls (at 100, 10, and 1
/388 TCID50/well, respectively) were included on each
/389 plate. Development of CPE was monitored by
/390 light microscopy and the titers were expressed as
/391 the reciprocal of the highest dilution of ascites,
/392 which neutralized 50% of virus infectivity (Scott et
/393 al., 1986).
/394 2.16. Hemolysis and hemolysis inhibition
/395 Both hemolysis (HL) and hemolysis inhibition
/396 (HLI) assays were performed according to the
/397 method of Norrby and Gollmar (1975).
/398 3. Results
/399 3.1. Generation of hybridoma clones specific for
/400 PPRV-HN protein
/401 From a single fusion, a total of 14 stably
/402 secreting parental clones were chosen. mAbs
/403 secreted by these clones were screened for their
/404 reactivities against PPRV-HN protein using ex-
/405 tracts from baculo recombinant HN virus-infected
/406 Sf921 cells, PPRV Nig75/, PPRV TN87/1 and
/407 RPV (RBOK) infected Vero cells in indirect
/408 ELISA. Four parental clones were selected on
/409 the basis of stable and moderately high secretion.
/410 They were then subcloned by end point limiting
/411 dilution to achieve monoclonality. One subclone
/412 from each parental clone was selected based on the
/413 reactivity in indirect ELISA. The selected sub-
/414 clones were termed as A6EA9, C10A1, D2E4 and
/415 F10E7. Isotyping ELISA with the hybridoma
/416 culture supernatants indicated that three subclones
/417 secrete antibodies of IgM isotype and the other
/418 one IgG2b and all the four mAbs were found to
/419 possess k light chain (Table 1).
/420 3.2. Characterization of PPRV-HN mAbs
/421 Ascitic fluids of all the four mAbs were gener-
/422 ated in Balb/c mice and assayed for their reactivity
/423 in ELISA. Three clones (C10A1, D2E4 and
/424 F10E7) were found to be cross-reactive with
/ 425RPV-H while A6E9 was not. All the four mAbs
/ 426recognized PPRV-HN from PPRV (Nig 75/1)
/ 427infected Vero cells as detected by intracellular
/ 428and cell surface immunofluorescence. Three of
/ 429them recognized RPV (RBOK) infected Vero cells,
/ 430while A6E9 did not react with H protein of RPV in
/ 431infected cells (Table 1). The immunofluorescence
/ 432pattern of reactivities is given in Fig. 1.
/ 433To determine whether these mAbs recognize
/ 434distinct or overlapping antigenic sites, competitive
/ 435binding assay was performed. F10E7 and A6E9
/ 436did not show competitive binding to PPRV-HN
/ 437antigen in the presence of any of the four mAbs,
/ 438while C10A1 and D2E4 competed with each other
/ 439and prevented binding of the competing antibody
/ 440to nearly 100% (Fig. 2).
/ 4413.3. Identification of regions on HN carrying B-cell
/ 442epitopes using deletion mutants
/ 443Western blot analysis employing the E. coli
/ 444expressed deletion mutants of RPV-H and PPRV-
/ 445HN proteins revealed that all the four mAbs
/ 446(A6E9, C10A1, D2E4 and F10E7) recognized
/ 447PPRV-HN deletions ND241 and ND262CD101,
/ 448while three mAbs (C10A1, D2E4 and F10E7)
/ 449recognized three RPV-H deletions ND448,
/ 450ND511 and ND359CD41 (Fig. 3). As expected,
/ 451the RPV-H non-cross-reactive mAb A6E9 did not
/ 452react with any of the RPV-H deletions tested (Fig.
/ 4533). From the immunoreactivity pattern using
/ 454PPRV-HN deletions, the antigenic sites recognized
/ 455by these four mAbs are localized to the region
/ 456263/508 aa and according to the immunoreactiv-
/ 457ity pattern with RPV-H deletions, the antigenic
/ 458domain of three mAbs C10A1, D2E4 and F10E7 is
/ 459in the region 512/568 aa. Extracts of CV1 cells
/ 460transfected with five PPRV-HN deletion mutants
/ 461were used for mAb reactivities in ELISA which
/ 462suggested that all the four PPRV-HN mAbs
/ 463reacted with four deletion mutants, namely
/ 464CD241, D385/537, ND508, D80/368 and not
/ 465with CD412 (Table 2) implying that the epitopes
/ 466for these mAbs perhaps lie in two discontinuous
/ 467regions 198/368 aa and 538/609 aa which are 171
/ 468aa apart.
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/471 To determine if the B-cell epitopes recognized by
/472 the mAbs are immunodominant, we carried out a
/473 competitive ELISA in which sera from sheep
/474 vaccinated with tissue culture PPRV vaccine were
/475 used as competitors for mAbs for binding to the
/476 corresponding epitopic sites, mapped in the pre-
/477 sent work (Fig. 4). The ascites of all four mAbs
/478 had titers of over 1000 in indirect ELISA using
/479 rECV and PPRV Nig75/1 infected cell lysate.
/480 Binding of three mAbs to their epitopes was
/481 inhibited by immune sera suggesting that these
/482 epitopes/epitopic regions are immunodominant
/483 (263/368 aa and 538/609 aa). The immunodomi-
/484 nant epitopic region as identified in the present
/485 work also contains sequences conserved in the
/486 neutralizing epitopes of H (587/592 aa) identified
/487 recently (Sugiyama et al., 2002) on the H protein
/488 of lapinized RPV.
/489 3.5. Inhibition of biological functions of HN
/490 The NA inhibition activity of various PPRV-
/491 HN mAbs were determined using two different
/492 substrates. The NI assay using substrate N -acetyl
/493 neuraminolactose indicated that two mAbs inhib-
/494 ited the NA with percent NA activity remaining at
/495 17.6% (D2E4) and 36.9% (A6E9) (Fig. 5A). With
/496 Fetuin as substrate, only D2E4 exhibited strong
/497 inhibitory activity (95%) as shown in Fig. 5B.
/498 All the four PPRV-HN mAbs showed HI
/499 activity with titers ranging from 100 to 400 (Table
/ 5003). Three PPRV-HN mAbs neutralized both PPR
/ 501and RP viruses with titers ranging from 10 to 40
/ 502(Table 3) while, A6E9 neutralized the homologous
/ 503(PPRV Nig 75/1) virus only.
/ 504To study whether binding of PPRV-HN mAbs
/ 505to HN protein inhibits the fusion promotion
/ 506activity, HLI assay was performed and the results
/ 507indicated that none of the PPRV-HN mAbs
/ 508inhibited the HL (Tables 3 and 4).
/ 5094. Discussion
/ 510Monoclonal antibodies are valuable tools in
/ 511identifying antigenic determinants and functional
/ 512domains of proteins. They are also useful in
/ 513distinguishing closely related viruses and therefore
/ 514are employed in diagnostic procedures for infec-
/ 515tious diseases. We have reported the generation of
/ 516mAbs to PPRV-HN protein in this study. As
/ 517PPRV-HN and RPV-H are antigenically closely
/ 518related, it is necessary to assess the cross-reactivity
/ 519of mAbs generated against PPRV-HN with RPV-
/ 520H and as expected, three of the four mAbs cross-
/ 521reacted with RPV-H. Three of the four mAbs
/ 522generated belong to IgM isotype and only one is
/ 523IgG2b. The IgG2b (D2E4) antibody has high
/ 524ELISA titer and was more stable than other three
/ 525IgM mAbs upon repeated freeze-thaw cycles.
/ 526The present work is the first report wherein
/ 527recombinant HN of PPRV produced in insect cells
/ 528has been used successfully to generate mAbs. The
/ 529immunoreactivity of three cross-reactive mAbs to
/ 530PPRV-HN and RPV-H deletions has identified the
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Table 1
Properties of PPRV-HN protein mAbs
PPRV-HN mAbs Antibody class Light chain Cross-reactivity with RPV Immunofluorescence (IF)
RPV (RBOK) PPRV (Nig 75/1)
Intracellular Cell surface Intracellular Cell surface
A6E9 IgM k / / / /// //
C10A1 IgM k // / /// // ///
D2E4 IgG 2b k /// /// /// /// ///
F10E7 IgM k / / // // //
/: Low reactivity in ELISA or IF; //: moderate reactivity in ELISA or IF; ///: high reactivity in ELISA or IF; /: negative
reaction in ELISA or IF.
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/531 mAb binding region as a discontinuous region
/532 between aa 263/368 and 538/568 and for the
/533 cross-reactive mAb (A6E9) to aa 263/368 and
/534 538/609 separated by 171 aa apart. This implies
/535 that all the four mAbs are binding to conforma-
/536 tion-dependent epitopes. The three mAbs are also
/ 537neutralizing, which suggests that the immunodo-
/ 538minant B-cell epitope/epitopic domain identified in
/ 539the present study are also of neutralizing nature.
/ 540Earlier work on glycoprotein B of pseudorabies
/ 541virus indicated that the discontinuous epitopes are
/ 542only partially expressed in recombinant fragments
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Fig. 1. Reactivity of PPRV-HN mAbs A6E9 and D2E4 by immunofluorescence staining of infected Vero cells: cells grown on
coverslips were infected with RPV (RBOK) (column 2) and PPRV (Nig 75/1) (column 3), column 1*/uninfected Vero cell control. At
48 h postinfection, only the coverslips intended for intracellular fluorescence study were fixed, rows (i) and (ii) coverslips were reacted
with A6E9 (1 in 1500) and rows (iii) and (iv) coverslips with D2E4 (1 in 2500). After washing, all the coverslips were reacted with
secondary antibody anti-mouse fluorescence isothiocyanate and the coverslips were examined under fluorescence microscope
(magnification, 10/).
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/543 (Zaripov et al., 1999). Further, Harper et al. (1990)
/544 have shown that there would be a partial restora-
/545 tion of the discontinuous epitopes in recombinant
/546 fragments just before Western blotting which
/547 enables binding of these mAbs to the respective
/548 regions with less intensity. Despite the lack of
/549 authentic higher-order structure of recombinant
/550 proteins when expressed in E. coli (Cason, 1994),
/551 the mAbs bind to the linear constituents of the
/ 552discontinuous regions in Western blot analysis.
/ 553The epitopes on two discontinuous regions, which
/ 554are 171 aa apart behave similar to the epitope
/ 555identified by Zaripov et al. (1999) for the glyco-
/ 556protein B of pseudorabies virus.
/ 557Comparison of deduced amino acid sequences
/ 558of the HN protein from 13 isolates of PPRV
/ 559(Shyam et al., unpublished observations) which
/ 560include four Indian isolates revealed that the
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Fig. 2. Competition of horseradish peroxidase conjugated and unconjugated PPRV-HN mAbs by different combinations. The PI
value is calculated by the formula, PI/100/[A/C]/[A/B]/100, wherein, A/OD490 in the absence of competitor (heterologous
mAb), B/OD490 in the presence of homologous mAb, C/OD pre-determined in the presence of competitor (heterologous mAb).
The concentration of the conjugated mAb is fixed against varying twofold dilutions of different PPRV-HN unconjugated mAbs, to
identify the overlapping and unique epitopes.
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/561 sequence in the region 527/552 is highly con-
/562 served, indicating conservation of B-cell epitopic
/563 regions. The region 263/368 aa and 538/609 aa
/564 where PPRV-HN mAbs bind may be assembled
/565 together in the tertiary structure of the HN protein
/566 to represent an antigenically conserved region.
/567 Using the four anti-HN mAbs, two distinct
/568 antigenic sites have been topographically mapped
/569 on the PPRV-HN molecule by competitive binding
/570 assay. A similar grouping based on C-ELISA has
/571 been reported for Sendai virus HN glycoprotein
/572 (Portner et al., 1987).
/573 Functional inhibition assays by different PPRV-
/574 HN mAbs of biological activities like neutraliza-
/575 tion of PPRV Nig 75/1 and RPV (RBOK) in VNT,
/576 inhibition of the NA activity upon binding to NA
/577 site of HN molecule by mAbs, measured using
/578 Fetuin and N -acetyl neuraminolactose as sub-
/579 strates, hemagglutination inhibition assay and HI
/580 activity using PPRV Nig 75/1 infected cell extract,
/581 gave very useful insights about the HN molecule.
/582 The results of all these assays suggested that the
/583 HN protein presented by the baculovirus recom-
/584 binant ‘‘resembles’’ the native protein of PPRV
/585 wild-type virus.
/586 As reported earlier by Iorio and Bratt (1984),
/587 the mAbs binding to different sites on the HN
/588 protein can be grouped depending on the extent of
/589 inhibition of NA activity with different substrates,
/590 since the inhibition varies with the site of their
/ 591binding. In this work, with Fetuin as the substrate
/ 592for NA, only one mAb D2E4 showed NI activity
/ 593(94.8% of activity being inhibited) and none of the
/ 594other mAbs showed inhibition, while two mAbs
/ 595(D2E4 and A6E9) showed inhibition with N -acetyl
/ 596neuraminolactose, a low molecular weight sub-
/ 597strate. Fetuin is a bulky molecule (m.w.: 43,000)
/ 598and is expected to be acted upon by part of HN
/ 599molecule responsible for NA activity to a greater
/ 600extent than N -acetyl neuraminolactose (m.w.: 633)
/ 601(Iorio and Bratt, 1984). In NI assay, the present
/ 602results indicated that one mAb (D2E4) is able to
/ 603inhibit NA activity with Fetuin, as against two
/ 604mAbs (D2E4 and A6E9) which showed NI activity
/ 605with N -acetyl neuraminolactose as the substrate;
/ 606the reason could be that the mAb A6E9 is of IgM
/ 607class, its affinity to the antigen is very weak as seen
/ 608in ELISA, Western blot and in kinetic analysis
/ 609(data not shown), the IgM mAb dissociates at a
/ 610much faster rate than IgG mAb. Because of its
/ 611huge size, Fetuin would have successfully com-
/ 612peted out A6E9 mAb from binding to epitope on
/ 613NA site, as compared with the smaller substrate,
/ 614N -acetyl neuraminolactose with reduced steric
/ 615hindrance of nearly 100-fold (Iorio and Bratt,
/ 6161984), increasing the likelihood of mAb A6E9 to
/ 617directly block NA site without much competition
/ 618by substrate N -acetyl neuraminolactose.
/ 619A significant observation is that D2E4 showed
/ 620more inhibitory activity than A6E9 with both the
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Fig. 2 (Continued)
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/621 substrates. There may be different binding sites on
/622 the NA active site of the HN molecule for these
/623 two mAbs. This prediction is supported by the
/624 observation that mAb A6E9 is non-cross-reactive
/625 with RPV-H protein, whereas D2E4 cross-reacts
/626 and further, these two mAbs do not compete with
/ 627each other in competitive binding assay, even
/ 628though the binding site lies in the region 263/
/ 629368 and 538/609 aa for A6E9 and 263/368 and
/ 630538/568 aa for D2E4. These results imply that
/ 631these two mAbs are binding to two different HN
/ 632sites on PPRV-HN.
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Fig. 3. (A) Schematic representation of overlapping deletion mutants: (i) fragments of PPRV-HN gene cloned in pRSET vectors and
expressed as His-tagged recombinant fragments in E. coli , (ii) fragments of PPRV-HN gene cloned in PCMX vector and transfected in
to CV1 cells and (iii) fragments of RPV-H gene cloned in pRSET vectors and expressed as His-tagged recombinant fragments in E.
coli. Boxes represent the portions of the gene retained in the respective deletion mutant and the numbers indicate the amino acids. (B,
C) Reactivity of PPRV-HN mAbs with PPRV-HN and RPV-H deletion proteins by Western immunoblot. Purified deletion proteins (1
mg) were electrophoressed on a 14% SDS polyacrylamide gel for panel (i), 12% for panel (ii), the blots were probed with mAbs (B)
A6E9 (1 in 1500) and (C) C10A1, D2E4 and F10E7 (1 in 2500). The PPRV-HN deletion proteins. Panel (i): Lane 1, ND241; Lane 2,
ND262CD101; and RPV-H deletion proteins; panel (ii): Lane 1, ND112CD427; Lane 2, ND448; Lane 3, ND112D183/424CD160; Lane
4, ND359CD41; and Lane 5 ND511 are expressed in E. coli . (C) is a representative Western blot with D2E4 mAb.
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/636 antibody D2E4 competes with C10A1 in compe-
/637 titive binding assay and both the mAbs bind to
/638 two discontinuous regions on the PPRV-HN
/639 protein. In addition to this, D2E4 possesses NI
/640 activity while C10A1 does not, which suggests that
/641 these two mAbs are binding to two different HN
/ 642sites on PPRV-HN within the mapped discontin-
/ 643uous region.
/ 644Out of four PPRV-HN mAbs, three bind to two
/ 645discontinuous regions separated by 171 aa (263/
/ 646368 and 538/568 aa sequence) and the fourth mAb
/ 647(A6E9) also binds to two discontinuous regions
/ 648separated by 171 aa (263/368 and 538/609 aa
/ 649sequence). One of the two binding sites falls in the
/ 650region beyond 538 aa (extreme carboxy terminal)
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Table 2
Reactivity of PPRV-HN mAbs with transfected cell extracts of HN deletion proteins in ELISA
PPRV-HN protein regions Name of the deletion fragment Reactivity in ELISA of PPRV-HN mAbs
A6E9 C10A1 D2E4 F10E7
1/368 aa CD241 / / / /
1/384 and 538/609 aa D385/537 / / / /
509/609 aa ND508 / / / /
1/79 and 369/609 aa D80/368 / / / /
1/197 aa CD412 / / / /
/: Signals with specific deletion protein fragment; /: negative with that specific deletion protein fragment. All the deletion
fragments reacted with polyclonal hyperimmune serum against PPRV.
Fig. 4. Identification of the immunodominant B-cell epitope/epitopic domain on PPRV-HN protein using mAbs A6E9, C10A1, D2E4
and F10E7 as tested by C-ELISA using vaccinated sheep sera as competing antibody. Bars 2/6 under each mAb represent 10 positive
sera from individual herds and bar 1 (N) represents average PI value of 10 negative sera from all the five herds (two samples per herd).
The PI value is calculated by the formula, PI/100/[OD in test well/OD in 0% control well]/100. PI more than 50 was considered as
positive for the presence of the PPRV-HN antibodies.
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/651 and two mAbs D2E4 and A6E9 possess NI
/652 activity. It has been shown recently that the
/653 residues DY at positions 283/284 contribute sig-
/ 654nificantly to NA activity (Shaguna and Shaila,
/ 655unpublished results). These two residues are ana-
/ 656logous to DY at position 300/301 of human
/ 657parainfluenza virus HN, which plays a role in the
/ 658NA activity (Bando et al., 1990) and these two
/ 659residues on PPRV-HN are within one of the two
/ 660discontinuous region on the PPRV-HN mAb
/ 661binding (263/368 aa) domain. Further, in other
/ 662paramyxoviruses, homology modeling has re-
/ 663vealed that R533 and Y551 residues may partici-
/ 664pate in substrate binding activity (Langedijk et al.,
/ 6651997). In the region of 527/552 aa in the sequence
/ 666of PPRV-HN, there is a 100% identity in 13 strains
/ 667(includes four Indian isolates) (Shyam et al.,
/ 668unpublished results) and also in 270/276 aa
/ 669sequence of PPRV-HN there is a 100% identity
/ 670in 10 strains with only Y to H change in three
/ 671African strains (Shyam et al., unpublished results).
/ 672Therefore, it is likely that the two mAbs D2E4 and
/ 673A6E9, which are binding to the highly conserved
/ 674regions on HN protein recognize the aa involved
/ 675in NA activity.
/ 676In accordance with the biological activities
/ 677affected by PPRV-HN mAbs, they could be
/ 678divided into three groups: group one comprising
/ 679of an mAb D2E4 which has HI activity, neutraliz-
/ 680ing both homologous and heterologous viruses,
/ 681cross-reacting with RPV in ELISA and possessing
/ 682NA inhibition activity with both Fetuin and N -
/ 683acetyl neuraminolactose substrates; the second
/ 684group consists of the mAb A6E9 with low HI
/ 685activity, neutralizing only homologous virus, non-
/ 686cross-reacting with heterologous virus (RPV-
/ 687RBOK) and possesses NI activity with substrate
/ 688N -acetyl neuraminolactose only; and the third
/ 689group showing all other activities except NI
/ 690activity (F10E7 and C10A1). PPRV-HN mAbs
/ 691can also be grouped based on their functional
/ 692inhibition properties in to four groups (HN sites).
/ 693HN site 1 (F10E7) possessing neutralization, HI
/ 694activities, does not compete with any mAb in C-
/ 695ELISA and also without NI and HLI activities.
/ 696HN site 2a (C10A1) possessing neutralization, HI
/ 697activities, competes with one mAb (D2E4) in C-
/ 698ELISA, but without NI and HLI activities. HN
/ 699site 2b (D2E4) possessing neutralization, HI
/ 700activities, competes with one mAb (C10A1) in C-
/ 701ELISA, also has NI activity and not HLI activity.
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Fig. 5. NI activity of PPRV-HN mAbs using (A) N -acetyl
neuraminolactose and (B) Fetuin as the substrate using PPPRV
Nig 75/1 infected cell lysate as antigen. Percent NA activity
inhibited/(OD of the test mAb after inhibition/OD of the
virus control)/100.
Table 3
Biological properties of PPRV-HN mAbs measured in terms of
functional activities
mAb characterization PPRV-HN mAbs
A6E9 C10A1 D2E4 F10E7
HI titera 200 200 400 100
VNTb
PPRV (Nig 75/1) 20 20 40 10
RPV (RBOK) 0 10 20 10
HLI titerc / / / /
/: No inhibition of HL by PPRV.
a Reciprocal dilutions of antibody which inhibits HA activity
of PPRV.
b Reciprocal dilution of antibody which neutralizes 50% of
the virus infectivity.
c Reciprocal dilution of antibody which inhibits HL of
PPRV.
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/702 HN site 3 (A6E9) possessing neutralization, HI
/703 activities, does not compete with other mAbs in C-
/704 ELISA, also has NI activity and no HLI activity.
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Table 4
Summary of functional inhibition properties of PPRV-HN antigenic sites using PPRV-HN mAbs
PPRV-HN mAbs designation HN site Virus neutralization (VN) NI HI HLI
Fetuin NANL
F10E7 1 / 0 0 / /
C10A1a 2a // 0 0 // /
D2E4 2b /// /// /// /// /
A6E9 3 // 0 // // /
/: No activity; /: low activity; //: moderate activity; ///: high activity.
a C10A1 subsite is involved in HI but not in NI activity.
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